Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RMC-5552

Small molecule · Inhibitor of mTORC1 (mechanistic target of rapamycin complex 1) (MTOR) · developed by Revolution Medicines

Phase 1 Most advanced trial (none active)
RVMD Developer
1 Registered trials

What is RMC-5552?

RMC-5552 is a bi-steric inhibitor of mTORC1, the raptor-containing mTOR complex, which blocks its serine/threonine kinase activity and suppresses phosphorylation of 4EBP1 and S6K1. It is being studied in glioblastoma and recurrent glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
mTORC1/4EBP1
Drug type
Small molecule
Targets
mTORC1 (mechanistic target of rapamycin complex 1) (MTOR), eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) (secondary target)
Mechanism
Inhibitor of mTORC1 (mechanistic target of rapamycin complex 1) (MTOR)
Pathways
PI3K/Akt/mTOR signaling, protein synthesis, cell cycle progression
Therapy area
Oncology
Developer
Revolution Medicines, Inc. (RVMD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
S6PL6DS4XK

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05557292 Phase 1 Glioblastoma Terminated RVMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

GlioblastomaRecurrent Glioblastoma

Other drugs acting on MTOR

More from Revolution Medicines

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RVMD page.

Follow RVMD, the company behind RMC-5552

See RVMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RVMD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.